Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An antibody treatment plus an immune-stimulating agent delayed viral rebound in primates infected with HIV-like virus.
Periodic infusions of such antibodies may eventually become a new way of treating the virus.
Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view.
Antibodies protect monkeys against SHIV.
This sets the stage for an early human trial of such antibody injections for use as pre-exposure prophylaxis (PrEP) against HIV.
Researchers are trying to harness the power of certain antibodies as long-acting injectable forms of HIV treatment or PrEP.
Three antibodies combined into one protected monkeys against a simian version of HIV, opening the door for human trials.
Researchers have succeeded in immunizing calves and prompting them to produce so-called broadly neutralizing antibodies against HIV.
This success is a major advance for vaccine research and may open the door for other important discoveries aiding vaccine and PrEP research.
This finding could aid the HIV vaccine research field.
The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.
They received two weeks of infusions of two antibodies after being infected with simian-human immunodeficiency virus (SHIV).
The discovery raises the chance of assembling an effective combination of antibodies that could be used in a vaccine or as treatment.
The powerful broadly neutralizing antibody could be developed as part of an HIV vaccine, as PrEP and as treatment for the virus.
Scientists succeed with new methods of spurring the immune system to manufacture broadly neutralizing antibodies against the virus.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.